A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva Clinical Trial

— FOPal  

Official title:

An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06089616
• Other study ID #: CLIN-60120-453
• Status: Not yet recruiting
• Start date: April 15, 2024
• Est. completion date: January 31, 2034

Study information

• Verified date: March 2024
• Source: Ipsen
• Contact: Ipsen Clinical Study Enquiries
• Phone: see email
• Email: clinical.trials[@]ipsen.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).

FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).

HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).

This registry study will take place in countries where the treatment, known as palovarotene has been approved for use. Participants will already be receiving palovarotene as prescribed by their treating physician according to locally approved product information.

The main aim of this study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.

This study will also describe the effectiveness of this treatment, including the effect on everyday activities and physical performance

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: January 31, 2034
• Est. primary completion date: December 31, 2033
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years and older

Eligibility

Inclusion Criteria :

• Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;

• Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.

Exclusion Criteria :

• Currently participating in a palovarotene clinical trial;

• Currently participating in any interventional clinical trial for FOP;

• Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

Related Conditions & MeSH terms

• Fibrodysplasia Ossificans Progressiva

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene	Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC).	From Baseline up to 30 days after the last palovarotene dose.
Primary	Percentage of Participants With Serious and Non-serious treatment-related TEAEs	Adverse events will be coded according to MedDRA and will be classified by PT and SOC.	From Baseline up to 30 days after the last palovarotene dose.
Primary	Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene	Adverse events will be coded according to MedDRA and will be classified by PT and SOC.	From Baseline up to 30 days after the last palovarotene dose.
Primary	Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.	Adverse events will be coded according to MedDRA and will be classified by PT and SOC.	From Baseline up to 30 days after the last palovarotene dose.
Secondary	Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score	The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved).	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in use of assistive devices	Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score	Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)	The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)	The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in absolute and percent predicted FEV1/FVC ratio	The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)	The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants =15 years old	PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows: Global physical health scores will be calculated as the sum of scores from Questions 3, 6, 7 and 8 and will range from 4 (worse health) to 20 (better health); Global mental health scores will be calculated as the sum of scores from Questions 2, 4, 5 and 10 and will range from 4 (worse health) to 20 (better health).	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old	PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health).; If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing.	From Baseline and every six months up to eleven years.
Secondary	Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall	The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit.	From Baseline and every six months up to eleven years.
Secondary	Number of flare-up outcomes	Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported.	From Baseline and every six months up to eleven years.
Secondary	Flare-up Duration	Flare-up duration will be assessed by body location and overall, at each visit.	From Baseline and every six months up to eleven years.
Secondary	Number of flare-ups		From 12 months before inclusion Baseline up to eleven years.
Secondary	Percentage of participants with new bone growth overall and by flare-up status	The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected.	From Baseline and every six months up to eleven years.
Secondary	Movement mobility change	Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement)	From Baseline and annualy up to eleven years.
Secondary	Number of locations impacted per participant		From Baseline and annualy up to eleven years.
Secondary	Evolution of impacted location (how many times a location is impacted) per location		From Baseline and annualy up to eleven years.
Secondary	Movement mobility outcomes		From Baseline and annualy up to eleven years.
Secondary	Mean dose/year of palovarotene for chronic treatment		From Baseline and every six months up to eleven years.
Secondary	Mean dose/cycle of palovarotene for flare-up treatment		From Baseline and every six months up to eleven years.
Secondary	Incidence of pregnancy	A pregnant participant will be followed throughout the pregnancy and the health status of the baby will be verified	From Baseline and every month up to 30 days of the last palovarotene dose.
Secondary	Description of pregnancy outcomes	A pregnant participant will be followed throughout the pregnancy.	From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days of the last palovarotene dose) and the health status of the baby will be verified up until one year of age
Secondary	Change from Baseline in height velocity	Height velocity will be derived for growing children.	From Baseline and every six months up to eleven years.
Secondary	Mean difference between chronological age and bone age	Bone age (assessment as per the SmPC/PI) will be collected for growing children. Chronological age will be derived for growing children.	From Baseline and every six months up to eleven years.
Secondary	Frequency of premature physeal closure overall	Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children.	From baseline up to 30 days of the last palovarotene dose
Secondary	Percentage of participants with any fractures overall	Assessed by radiological imaging and clinical examination.	From baseline up to 30 days of the last palovarotene dose